Recombinant LAG3 (Relatlimab Biosimilar) 抗体
This anti-LAG3 (Relatlimab Biosimilar) antibody is a 小鼠 单克隆 antibody detecting LAG3 (Relatlimab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant LAG3 (Relatlimab Biosimilar) 抗体 (ABIN7795123)
抗原
LAG3 (Relatlimab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
小鼠
克隆类型
单克隆
标记
This LAG3 (Relatlimab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody
-
产品特性
- What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human LAG-3
-
-
anti-LAG3 (Relatlimab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Human Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- LAG3 (Relatlimab Biosimilar)
-
别名
- Relatlimab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
